Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TMPMK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PHN-010
|
|||||
| Synonyms |
PHN-010
Click to Show/Hide
|
|||||
| Organization |
Pheon Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
TOP1 inhibitor
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Cervical cancer |
1 Trials
|
||||||||
| Colorectal cancer |
1 Trials
|
||||||||
| Endometrial cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key eligibility: Adults with progressive CRC/ovarian/endometrial/cervical/NSCLC cancers after ≥1 prior therapy, measurable disease, ECOG 0-1. Major exclusions: prior topoisomerase-1 ADC treatment, uncontrolled CNS metastases, Grade >1 residual toxicity, active infections/NIP-ILD, or recent anticancer therapies/surgeries.
|
||||
| Administration Dosage |
PHN-010 is administered intravenously.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06457997 | Clinical Status | PHASE1 | ||
| Clinical Description | First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include DLT incidence (Phase 1a, 18 months), AE/SAE monitoring (Phase 1a/1b, 18 months), dose modification frequency (18 months), and ORR assessment (Phase 1b, 36 months) in advanced solid tumors.
|
||||
| Other Endpoint |
Secondary objectives encompass efficacy measures (BOR, DCR, PFS, TTR, OS, CA-125 response, 36 months), comprehensive PK analysis (Cmax/Tmax/AUC/t1/2 for ADC components, 36 months), and immunogenicity (ADA concentration, 36 months).
|
||||